Clinical trialNCT02926690RecruitingPhase 1Interventional

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

SponsorOncoTherapy Science, Inc.Enrollment70Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Norwalk Hospital
Norwalk, Connecticut, United States
Completed
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States
Shipra Gandhi, MD, MS
Recruiting
Kapi'Olani Medical Center for Women & Children
Honolulu, Hawaii, United States
Jami Fukui, MDNaoto Ueno, MD, PhD, FACP
Recruiting
Dartmouth Cancer Center/dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Muhammad Z Afzal, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Completed
Weill Cornell Medicine | Newyork-Presbyterian
New York, New York, United States
Completed
Md Anderson Cancer Center
Houston, Texas, United States
Completed
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Yee Chung Cheng, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OTS167PO

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 May 2017
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 25 Feb 2026
Registered enrollment: 70
Registry id: NCT02926690

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.